Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

GoodRx Holdings, Inc. - Class A Common Stock (NQ:GDRX)

4.370 -0.110 (-2.46%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about GoodRx Holdings, Inc. - Class A Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
GDRX Q1 Earnings Call: Management Focuses on Pharmacy Partnerships and Marketplace Evolution
Healthcare tech company GoodRx (NASDAQ:GDRX) met Wall Street’s revenue expectations in Q1 CY2025, with sales up 2.6% year on year to $203 million. The company’s outlook for the full year was close to... 
Via StockStory
Topics Bankruptcy
Exposures Financial Legal
3 Small-Cap Stocks Facing Headwinds
Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and their stock prices) often stay small... 
Via StockStory
GoodRx Launches New Erectile Dysfunction Subscription Service to Simplify Access and Eliminate Treatment Barriers
From GoodRx
Via Business Wire
Earnings Scheduled For May 7, 2025
Via Benzinga
The Analyst Verdict: GoodRx Holdings In The Eyes Of 4 Experts
Via Benzinga
GoodRx Launches Community Link to Offer Independent Pharmacies Cost-Plus Pricing
From GoodRx
Via Business Wire
3 Stocks Under $10 with Mounting Challenges
Stocks trading in the $1-10 range are generally smaller players with less risk than their penny stock counterparts. But that doesn’t mean the underlying businesses are cheap, and we advise caution as... 
Via StockStory
GoodRx Open Sources Lifecycle to Support Innovation in Software Development Velocity and Developer Productivity
From GoodRx
Via Business Wire
Healthcare Technology Stocks Q1 Recap: Benchmarking GoodRx (NASDAQ:GDRX)
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q1. Today, we are looking at healthcare technology stocks, starting... 
Via StockStory
GoodRx to Launch Direct Contracting for Independent Community Pharmacies
From GoodRx
Via Business Wire
GoodRx Offers Value Proposition As Pharmacy Costs Shifts To Consumers: Analyst
J.P. Morgan analyst revises outlook on GoodRx Holdings following Q1 earnings, reaffirms Overweight rating and $7 price target. 
Via Benzinga
Demystifying GoodRx Holdings: Insights From 5 Analyst Reviews
Via Benzinga
Why GoodRx Holdings Stock Triumphed on Thursday
Via The Motley Fool
GoodRx’s (NASDAQ:GDRX) Q1 Earnings Results: Revenue In Line With Expectations, Stock Jumps 10.3%
Healthcare tech company GoodRx (NASDAQ:GDRX) met Wall Street’s revenue expectations in Q1 CY2025, with sales up 2.6% year on year to $203 million. The company’s outlook for the full year was close to... 
Via StockStory
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
GoodRx Reports First Quarter 2025 Results
From GoodRx Holdings, Inc.
Via Business Wire
GoodRx (GDRX) Reports Earnings Tomorrow: What To Expect
Healthcare tech company GoodRx (NASDAQ:GDRX) will be reporting results tomorrow after the bell. Here’s what you need to know. 
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
3 Reasons to Sell GDRX and 1 Stock to Buy Instead
GoodRx’s stock price has taken a beating over the past six months, shedding 30.4% of its value and falling to $4.55 per share. This was partly driven by its softer quarterly results and may have... 
Via StockStory
Topics Supply Chain
Exposures Supply Chain
3 Healthcare Stocks with Questionable Fundamentals
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. But financial performance has lagged recently as players offloaded surplus COVID... 
Via StockStory
Topics Stocks
Exposures COVID-19 US Equities
3 of Wall Street’s Favorite Stocks Showing Warning Signs
Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional... 
Via StockStory
Healthcare Technology Stocks Q4 In Review: Hims & Hers Health (NYSE:HIMS) Vs Peers
Let’s dig into the relative performance of Hims & Hers Health (NYSE:HIMS) and its peers as we unravel the now-completed Q4 healthcare technology earnings season. 
Via StockStory
GoodRx Announces Date for First Quarter 2025 Earnings Release and Conference Call
From GoodRx Holdings, Inc.
Via Business Wire
GoodRx Introduces New E-commerce Experience for Retail Pharmacies
From GoodRx
Via Business Wire
3 Small-Cap Stocks in Hot Water
Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and their stock prices) often stay small... 
Via StockStory
GoodRx Appoints Aaron Crittenden as President of Rx Marketplace and Scott Pope, PharmD, as Chief Pharmacy Officer and Head of Clinical Engagement
From GoodRx
Via Business Wire
3 Stocks Under $10 Skating on Thin Ice
Stocks trading in the $1-10 range are generally smaller players with less risk than their penny stock counterparts. But that doesn’t mean the underlying businesses are cheap, and we advise caution as... 
Via StockStory
GoodRx Report Reveals Striking Gender Divide in Prescription Medication Spending
From GoodRx
Via Business Wire
GoodRx (GDRX) Q4 2024 Earnings Call Transcript
GDRX earnings call for the period ending December 31, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
GoodRx Reports Mixed Q4: Pharma Strength Amid Subscription Decline, Sluggish Prescription Sales
GoodRx reported Q4 revenue of $198.6M, missing expectations. 2025 guidance projects $810M–$840M revenue and adjusted EBITDA of $270M–$286M. 
Via Benzinga
GoodRx (NASDAQ:GDRX) Misses Q4 Revenue Estimates
Healthcare tech company GoodRx (NASDAQ:GDRX) missed Wall Street’s revenue expectations in Q4 CY2024, with sales flat year on year at $198.6 million. On the other hand, the company expects next... 
Via StockStory
< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.